Skip to search formSkip to main contentSkip to account menu

ONX 0912

Known as: Proteasome Inhibitor ONX 0912 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Oligopeptides

Narrower (1)

oprozomib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Overexpression of immunoproteasome low-molecular-mass polypeptide 7 and inhibiting role of next-generation proteasome inhibitor ONX 0912 on cell growth in glioma.
OBJECTIVES The aim of this study was to determine the expression level of immunoproteasome and its clinical significance in… 
2011
2011
Epoxyketone-Based Proteasome Inhibitors Carfilzomib and Orally Bioavailable ONX 0912 Have Anti-Resorptive and Bone-Anabolic Activity in Addition to Anti-Myeloma Effects
Abstract 2906 Background: Multiple myeloma (MM), a hematological malignancy of terminally differentiated plasma cells, is closely… 
2011
2011
Abstract 541: The oral proteasome inhibitor ONX 0912 has bone anabolic effects in addition to anti-myeloma effects
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Multiple Myeloma (MM) is a cancer of antibody producing… 
2011
2011
Abstract 584: The novel proteasome inhibitors carfilzomib and ONX 0912 potently induce apoptosis and autophagy in head and neck squamous cell carcinoma cells via alteration of Bcl-2 family members
The goal of this study was to investigate the impact and molecular mechanism of action of two novel proteasome inhibitors… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)